deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT04305197

A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)

A Phase Ib/IIa Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerance, Pharmacokinetics/ Pharmacodynamics(PK/PD) of ICP-022 in Patients With Mild and Moderate Systemic Lupus Erythematosus

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.

Conditions Systemic Lupus Erythematosus
Interventions ICP-022 Placebos
Updated 9 times since 2020 Last updated: Nov 28, 2022 Started: Jul 9, 2020 Primary completion: Apr 28, 2022 Completion: Apr 28, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04305197, this PHASE1/PHASE2 trial focuses on Systemic Lupus Erythematosus and remains completed. Sponsored by Beijing InnoCare Pharma Tech Co., Ltd., it has been updated 9 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Apr 2020 – ~Aug 2020 · 4 months · monthly snapshot~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Sep 2022 · 15 months · monthly snapshotRecruiting~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Dec 2022 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  4. Sep 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Jun 2021 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 4 earlier versions

  1. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE1_PHASE2

  2. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  3. Aug 2020 — Nov 2020 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  4. Apr 2020 — Aug 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Beijing InnoCare Pharma Tech Co., Ltd.
Data source: Beijing InnoCare Pharma Tech Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations